Metabolism
How quickly a medicine is metabolised, or a prodrug is activated.
PHARMACOGENETICS · PGx WITH WGS
Are your medicines causing side effects?
Your genetic information can help your clinician personalise treatment.
Pharmacogenetic analysis through WGS gives your clinician genetic information to support the selection and dosing of specific medicines.
DNA IN TREATMENT
The same medicine. A different response.
Genetic differences can affect how the body metabolises or responds to specific medicines. Pharmacogenetics turns that knowledge into information your treating clinician can use.
Response
Genetic information that may be associated with response to specific treatments.
Tolerability
Identification of certain genetic factors associated with adverse effects.
DNA + current medication + clinical history → personalised clinical assessment.
FROM SAMPLE TO INFORMATION
A simple sample. Information with a clinical purpose.
The test can start with a buccal swab. WGS provides the genomic data, while pharmacogenetic interpretation focuses on relevant gene–drug relationships.
The testing pathway
01Buccal swab
Sample collection following NeoScreen instructions.
02WGS analysis
Genome sequencing and quality assessment.
03PGx interpretation
Evaluation of relevant genetic findings.
04Report for the clinician
Clinical review alongside treatment and history.
PHARMACOGENETICS WITH WGS
The genome provides the data. Interpretation provides the value.
Whole-genome data supports focused pharmacogenetic assessment. The clinical report depends on validated methods, data quality and the evidence for each association.
Three layers of clinical information
Genetic data
Findings in pharmacogenetic genes.
Functional interpretation
Assessment of predicted function where supported by evidence.
Relevance to medicines
Links to selected guidelines and medicine information.
CYP2D6
Included in our analysis.
An important pharmacogene for selected antidepressants, analgesics and other medicines. Findings are interpreted using the laboratory’s validated methodology and the detection capabilities for each variant type.
WHERE IT CAN HELP
Information for specific medicines.
Evidence applies to specific medicines within each category. The test does not determine, on its own, which medicine a person should take.
Antiplatelets
Selected associations involving activation and treatment response.
Anticoagulants
Genetic factors that may contribute to treatment assessment.
Statins
Information on selected associations with muscle-related adverse effects.
Selected antidepressants
Gene–drug relationships that can support clinical treatment selection or adjustment.
Selected analgesics
Genetic differences in the metabolism or activation of certain medicines.
A REPORT FOR CLINICAL USE
Your result gains meaning with your clinician.
The report organises findings and their interpretation. Treatment decisions also consider age, kidney and liver function, other medicines and the full clinical history.
Genetic findings
Reportable findings and predicted functional significance where this can be assigned.
Evidence-informed interpretation
Relationships with specific medicines, supporting sources and relevant limitations.
Do not change or stop medication without consulting your treating clinician.
VISUAL GUIDE · PGx
Medicines, genes and CYP2D6 structures in pictures.
Educational examples from NeoScreen information material. Select an image to view it at full resolution.
Colour-coded medicines table
An illustrative colour-coded presentation of pharmacogenetic information for medicines.
Full resolution · opens in a new tab ↗
Genes & alleles
Genes and illustrative allele / haplotype entries.
Full resolution · opens in a new tab ↗
CYP2D6 · Structural variants
CYP2D6: deletions, duplications and hybrid structures.
Full resolution · opens in a new tab ↗Allele / haplotype entries are reference information, not counts of unique SNPs or patient mutations.
The images are educational examples, not individual results or treatment instructions.
Image references
SCIENTIFIC EVIDENCE
The evidence behind pharmacogenetics.
International resources for interpreting established associations and using available genetic results in clinical practice.
Table of Pharmacogenetic Associations
A table of selected gene–drug associations. Inclusion does not mean that genetic testing is required for every medicine or every patient.
FDA · Precision medicineView source ↗CPIC Guidelines
Guidelines on how available genotype results can inform specific treatment decisions. They do not determine whether everyone should be tested.
CPIC · Gene–drug guidelinesView source ↗COMMON QUESTIONS
The key answers, clearly.
Pharmacogenetics is one part of personalised care.
Will I learn whether all my medicines are suitable?
The test provides information on specific established gene–drug relationships. It does not cover every cause of reduced efficacy or adverse effects and does not replace clinical assessment.
Is a blood draw needed?
A buccal swab can be used according to laboratory instructions. Our team will advise on the appropriate sample for your case.
Can I change my treatment myself?
No. Your treating clinician decides on medicine selection, dosage and any change or discontinuation.
Can WGS data be reassessed?
Reassessment may be considered when new evidence or clinical needs arise, in line with laboratory policy and your consent.
The next step starts with a conversation.
The NeoScreen team can explain the test, sample collection and coordination with your clinician.
